{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T20:06:22Z","timestamp":1795032382503,"version":"4.10.2"},"reference-count":53,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Endocrinology &amp; Metabolism"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.beem.2023.101782","type":"journal-article","created":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T02:04:58Z","timestamp":1683597898000},"page":"101782","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":106,"title":["Bone health and menopause: Osteoporosis prevention and treatment"],"prefix":"10.1016","volume":"38","author":[{"given":"Tobie J.","family":"de Villiers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beem.2023.101782_bib1","unstructured":"Cooper C. and Ferrari S. IOF compendium of osteoporosis. \u3008https:\/\/www.osteoporosis.foundation\u3009. Accessed March 2023."},{"key":"10.1016\/j.beem.2023.101782_bib2","first-page":"115","article-title":"Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis","volume":"21","author":"Manolagas","year":"2000","journal-title":"Endocr Rev"},{"key":"10.1016\/j.beem.2023.101782_bib3","doi-asserted-by":"crossref","first-page":"6460","DOI":"10.1038\/s41598-017-06614-0","article-title":"Estrogen regulates bone turnover by targeting RANKL expression in bone lining cells","volume":"7","author":"Streicher","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.beem.2023.101782_bib4","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.tem.2012.03.008","article-title":"Estrogen and the skeleton","volume":"23","author":"Khosla","year":"2012","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.beem.2023.101782_bib5","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/gme.0b013e31824d8f40","article-title":"Executive summary of the stages of reproductive aging workshop + 10: addressing the unfinished agenda of staging reproductive aging","volume":"19","author":"Harlow","year":"2012","journal-title":"Menopause"},{"key":"10.1016\/j.beem.2023.101782_bib6","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1056\/NEJM199208273270908","article-title":"The prevention and treatment of osteoporosis","volume":"327","author":"Riggs","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beem.2023.101782_bib7","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1210\/jc.2007-1876","article-title":"Bone mineral density changes during the menopause transition in a multiethnic cohort of women","volume":"93","author":"Finkelstein","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2023.101782_bib8","unstructured":"America\u2019s Bone Health: The State of Osteoporosis and Low Bone Mass in Our Nation. Washington, DC: National Osteoporosis Foundation; 2002."},{"key":"10.1016\/j.beem.2023.101782_bib9","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/0002-9343(93)90218-E","article-title":"Consensus development conference","volume":"94","year":"1993","journal-title":"Am J Med"},{"key":"10.1016\/j.beem.2023.101782_bib10","unstructured":"ISCD : Official adult positions. 2019. Iscd.org. Accessed March 2023."},{"key":"10.1016\/j.beem.2023.101782_bib11","unstructured":"Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report 1994."},{"key":"10.1016\/j.beem.2023.101782_bib12","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1001\/jama.286.22.2815","article-title":"Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment","volume":"286","author":"Siris","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.beem.2023.101782_bib13","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1097\/GME.0000000000001831","article-title":"Management of osteoporosis in postmenopausal women: the 2021 position statement of the North American Menopause Society","volume":"28","year":"2021","journal-title":"Menopause"},{"key":"10.1016\/j.beem.2023.101782_bib14","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3109\/13697137.2012.659975","article-title":"The WHI: the effect of hormone replacement therapy on fracture prevention","volume":"15","author":"De Villiers","year":"2012","journal-title":"Climacteric"},{"key":"10.1016\/j.beem.2023.101782_bib15","unstructured":"Clinician\u2019s Guide to Prevention and Treatment of Osteoporosis. National Osteoporosis Foundation (USA) Guidelines. \u3008http:\/\/www.nof.org\u3009 Accessed March 2023."},{"key":"10.1016\/j.beem.2023.101782_bib16","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.bpobgyn.2008.10.009","article-title":"Bone health and osteoporosis in postmenopausal women","volume":"23","author":"De Villiers","year":"2009","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"Supplement1","key":"10.1016\/j.beem.2023.101782_bib17","first-page":"1","article-title":"The National Osteoporosis Foundation of South Africa Guidelines","volume":"22","year":"2017","journal-title":"JEMDSA"},{"key":"10.1016\/j.beem.2023.101782_bib18","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s11657-018-0510-0","article-title":"A brief history of FRAX","volume":"13","author":"Kanis","year":"2018","journal-title":"Arch Osteoporos"},{"key":"10.1016\/j.beem.2023.101782_bib19","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00198-017-4341-4","article-title":"FRAX-based intervention and assessment thresholds in several Latin American countries","volume":"29","author":"Clark","year":"2018","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2023.101782_bib20","doi-asserted-by":"crossref","unstructured":"Masud T., Binkley N., Boonen S., et al. Official Positions for FRAX clinical regarding falls and frailty: can falls and frailty be used in FRAX. From Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX. J Clin Densitom 2011;14:194\u2013204.","DOI":"10.1016\/j.jocd.2011.05.010"},{"key":"10.1016\/j.beem.2023.101782_bib21","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1002\/jbmr.3538","article-title":"Comparison of methods for improving fracture risk assessment in diabetes: the Manitoba BMD Registry","volume":"33","author":"Leslie","year":"2018","journal-title":"J Bone Min Res"},{"key":"10.1016\/j.beem.2023.101782_bib22","unstructured":"NATAP. Clinician\u2019s guide to prevention and treatment of osteoporosis (National Osteoporosis Foundation Guidelines). Available at: \u3008www.natap.org\/2008\/HIV\/070708_01.htm\u3009. Accessed March 2023."},{"key":"10.1016\/j.beem.2023.101782_bib23","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s00198-008-0712-1","article-title":"The National Osteoporosis Guideline Group. Case finding for the management of osteoporosis with FRAX \u2013 assessment and intervention thresholds for the UK","volume":"19","author":"Kanis","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2023.101782_bib24","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1007\/s00198-015-3176-0","article-title":"FRAX-based assessment and intervention thresholds; exploration of thresholds in women aged 50 years and older in the UK","volume":"26","author":"McCloskey","year":"2015","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2023.101782_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00198-019-05176-3","article-title":"Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures","volume":"31","author":"Kanis","year":"2020","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2023.101782_bib26","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1080\/13697137.2021.1950967","article-title":"Update on bone health: the international menopause society white paper 2021","volume":"24","author":"De Villiers","year":"2021","journal-title":"Climacteric"},{"key":"10.1016\/j.beem.2023.101782_bib27","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1001\/jama.1941.02820220007002","article-title":"Postmenopausal osteoporosis","volume":"161","author":"Albright","year":"1941","journal-title":"JAMA"},{"key":"10.1016\/j.beem.2023.101782_bib28","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1136\/bmj.2.6094.1087-a","article-title":"Effect of oestrogens on postmenopausal bone loss","volume":"2","author":"Lindsay","year":"1977","journal-title":"Br Med J"},{"key":"10.1016\/j.beem.2023.101782_bib29","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1001\/jama.1996.03540170033029","article-title":"Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen\/ progestin interventions (PEPI) trial","volume":"276","author":"The Writing Group for the PEPI","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.beem.2023.101782_bib30","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women\u2019s Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.beem.2023.101782_bib31","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/jama.290.13.1729","article-title":"Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women\u2019s Health Initiative randomized trial.","volume":"290","author":"Cauley","year":"2003","journal-title":"JAMA"},{"issue":"Suppl 2","key":"10.1016\/j.beem.2023.101782_bib32","first-page":"1","article-title":"8th Pieter van Keep Memorial Lecture. Estrogen and bone: have we completed a full circle?","volume":"17","author":"De Villiers","year":"2014","journal-title":"Climacteric"},{"key":"10.1016\/j.beem.2023.101782_bib33","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/13697137.2016.1196047","article-title":"Revised global consensus statement on menopausal hormone therapy","volume":"19","author":"De Villiers","year":"2016","journal-title":"Climacteric"},{"key":"10.1016\/j.beem.2023.101782_bib34","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1080\/13697137.2021.1915271","article-title":"Fracture recurrence in hip fracture with menopausal hormone therapy versus risedronate: a clinical trial","volume":"24","author":"Park","year":"2021","journal-title":"Climacteric"},{"key":"10.1016\/j.beem.2023.101782_bib35","first-page":"24","article-title":"Using menopausal hormone therapy to prevent fracture recurrence in older women: is it time to change our opinion","author":"De Villiers","year":"2021","journal-title":"Editor Clima"},{"key":"10.1016\/j.beem.2023.101782_bib36","article-title":"The management of vasomotor symptoms of menopause (VMS) with menopausal hormone therapy (MHT)","volume":"27","author":"De Villiers","year":"2022","journal-title":"Curr Opin Endocr Metab Res"},{"key":"10.1016\/j.beem.2023.101782_bib37","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3109\/13697137.2015.1129166","article-title":"2016 IMS recommendations on women\u2019s midlife health and menopause hormone therapy","volume":"19","author":"Baber","year":"2016","journal-title":"Climacteric"},{"key":"10.1016\/j.beem.2023.101782_bib38","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1210\/jc.2019-00221","article-title":"Pharmacological management of osteoporosis in postmenopausal women Eastell R, Rosen CJ, Black DM, et al. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society Clinical Practice Guideline.","volume":"104","author":"Eastell","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2023.101782_bib39","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomized clinical trial","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.beem.2023.101782_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/13697130903568542","article-title":"Bazedoxifene: a novel selective estrogen receptor modulator for postmenopausal osteoporosis","volume":"13","author":"De Villiers","year":"2010","journal-title":"Climacteric"},{"key":"10.1016\/j.beem.2023.101782_bib41","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.amjmed.2012.06.023","article-title":"Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday","volume":"126","author":"McClung","year":"2013","journal-title":"Am J Med"},{"key":"10.1016\/j.beem.2023.101782_bib42","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/jbmr.2442","article-title":"The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-pivotal fracture trial (PFT)","volume":"30","author":"Black","year":"2015","journal-title":"J Bone Min Res"},{"key":"10.1016\/j.beem.2023.101782_bib43","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s11657-022-01061-5","article-title":"UK clinical guideline for the prevention and treatment of osteoporosis","volume":"17","author":"Gregson","year":"2022","journal-title":"Arch Osteoporos"},{"key":"10.1016\/j.beem.2023.101782_bib44","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.2147\/DDDT.S270829","article-title":"A review on the role of denosumab in fracture prevention","volume":"14","author":"Pang","year":"2020","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.beem.2023.101782_bib45","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.beem.2023.101782_bib46","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beem.2023.101782_bib47","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s00198-020-05718-0","article-title":"Long\u2010term cancer surveillance: results from the Forteo patient registry surveillance study","volume":"32","author":"Gilsenan","year":"2021","journal-title":"Osteoporos Int"},{"issue":"316","key":"10.1016\/j.beem.2023.101782_bib48","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of Abaloparatide vs Placebo on new vertebral fractures in postmenopausal women with osteoporosis","volume":"16","author":"Miller","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.beem.2023.101782_bib49","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.maturitas.2014.04.013","article-title":"Wnt signaling and osteoporosis","volume":"78","author":"Manolagas","year":"2014","journal-title":"Maturitas"},{"key":"10.1016\/j.beem.2023.101782_bib50","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab Treatment in Postmenopausal Women with Osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beem.2023.101782_bib51","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11914-020-00652-w","article-title":"Romosozumab: a review of efficacy, safety, and cardiovascular risk","volume":"19","author":"Fixen","year":"2021","journal-title":"Curr Osteoporos Rep"},{"key":"10.1016\/j.beem.2023.101782_bib52","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","article-title":"Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO); a multicentre double- blind, double- dummy randomised controlled trial","volume":"391","author":"Kendler","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2023.101782_bib53","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"}],"container-title":["Best Practice &amp; Research Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X23000568?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X23000568?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:00:00Z","timestamp":1761498000000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X23000568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S1521690X23000568"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2023.101782","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bone health and menopause: Osteoporosis prevention and treatment","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2023.101782","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101782"}}